SDGR (Schrodinger) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SDGR Schrodinger Inc SDGR
73 GF Score
Price $17.81
GF Value $25.98
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Schrodinger SpecialCharges?

Special Charges only applies to banks.

SDGR
73GF Score
Schrodinger Inc SDGR
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Schrodinger (SDGR) Overvalued in 2026?

Based on GuruFocus' analysis, Schrodinger stock appears to be undervalued. The current stock price of $17.81 is trading 31.4% below its estimated GF Value™ of $25.98. GuruFocus considers Schrodinger to be Possible Value Trap.

Key valuation signals for SDGR:

  • SpecialCharges:
  • GF Value™: $25.98 vs. price of $17.81 (31.4% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SDGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Schrodinger Business Description

Other Exchanges 43Z:Germany
Address 1540 Broadway, 24th Floor, New York, NY, USA, 10036
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
73GF Score

Get the complete analysis for SDGR

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.81
Price
$25.98
GF Value